View in EDS

Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.

Saved in:
Bibliographic Details
Title: Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.
Authors: Khanani AM; Sierra Eye Associates, Reno, Nevada; University of Nevada, Reno School of Medicine, Reno, Nevada. Electronic address: arshad.khanani@gmail.com., Danzig CJ; Department of Surgery, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida., Heier JS; Ophthalmic Consultants of Boston, Boston, Massachusetts., Jaffe GJ; Department of Ophthalmology, Duke University, Durham, North Carolina., Kaiser PK; Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio., Lally DR; New England Retina Consultants, Springfield, Massachusetts., Patel SS; West Texas Retina Consultants, Abilene, Texas., Vajzovic L; Department of Ophthalmology, Duke University, Durham, North Carolina., Weng CY; Department of Ophthalmology, Baylor College of Medicine, Houston, Texas., Patel H; Astellas Pharma Inc., Northbrook, Illinois., Clark J; Astellas Pharma Inc., Northbrook, Illinois., Desai D; Astellas Pharma Inc., Northbrook, Illinois., Luo D; Astellas Pharma Inc., Northbrook, Illinois., Henry E; Astellas Pharma Inc., Northbrook, Illinois., Holz FG; Department of Ophthalmology, University of Bonn, Bonn, Germany.
Corporate Authors: GATHER2 Trial Investigators
Source: Ophthalmology [Ophthalmology] 2026 Apr; Vol. 133 (4), pp. 451-465. Date of Electronic Publication: 2025 Dec 15.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41407269
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Khanani+AM%22">Khanani AM</searchLink>; Sierra Eye Associates, Reno, Nevada; University of Nevada, Reno School of Medicine, Reno, Nevada. Electronic address: arshad.khanani@gmail.com.<br /><searchLink fieldCode="AU" term="%22Danzig+CJ%22">Danzig CJ</searchLink>; Department of Surgery, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida.<br /><searchLink fieldCode="AU" term="%22Heier+JS%22">Heier JS</searchLink>; Ophthalmic Consultants of Boston, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Jaffe+GJ%22">Jaffe GJ</searchLink>; Department of Ophthalmology, Duke University, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Kaiser+PK%22">Kaiser PK</searchLink>; Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.<br /><searchLink fieldCode="AU" term="%22Lally+DR%22">Lally DR</searchLink>; New England Retina Consultants, Springfield, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Patel+SS%22">Patel SS</searchLink>; West Texas Retina Consultants, Abilene, Texas.<br /><searchLink fieldCode="AU" term="%22Vajzovic+L%22">Vajzovic L</searchLink>; Department of Ophthalmology, Duke University, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Weng+CY%22">Weng CY</searchLink>; Department of Ophthalmology, Baylor College of Medicine, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Patel+H%22">Patel H</searchLink>; Astellas Pharma Inc., Northbrook, Illinois.<br /><searchLink fieldCode="AU" term="%22Clark+J%22">Clark J</searchLink>; Astellas Pharma Inc., Northbrook, Illinois.<br /><searchLink fieldCode="AU" term="%22Desai+D%22">Desai D</searchLink>; Astellas Pharma Inc., Northbrook, Illinois.<br /><searchLink fieldCode="AU" term="%22Luo+D%22">Luo D</searchLink>; Astellas Pharma Inc., Northbrook, Illinois.<br /><searchLink fieldCode="AU" term="%22Henry+E%22">Henry E</searchLink>; Astellas Pharma Inc., Northbrook, Illinois.<br /><searchLink fieldCode="AU" term="%22Holz+FG%22">Holz FG</searchLink>; Department of Ophthalmology, University of Bonn, Bonn, Germany.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22GATHER2+Trial+Investigators%22">GATHER2 Trial Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227802443%22">Ophthalmology</searchLink> [Ophthalmology] 2026 Apr; Vol. 133 (4), pp. 451-465. <i>Date of Electronic Publication: </i>2025 Dec 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7802443 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-4713 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201616420%22">01616420 </searchLink><i>NLM ISO Abbreviation: </i>Ophthalmology <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41407269
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ophtha.2025.12.011
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 451
    Titles:
      – TitleFull: Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Khanani AM
      – PersonEntity:
          Name:
            NameFull: Danzig CJ
      – PersonEntity:
          Name:
            NameFull: Heier JS
      – PersonEntity:
          Name:
            NameFull: Jaffe GJ
      – PersonEntity:
          Name:
            NameFull: Kaiser PK
      – PersonEntity:
          Name:
            NameFull: Lally DR
      – PersonEntity:
          Name:
            NameFull: Patel SS
      – PersonEntity:
          Name:
            NameFull: Vajzovic L
      – PersonEntity:
          Name:
            NameFull: Weng CY
      – PersonEntity:
          Name:
            NameFull: Patel H
      – PersonEntity:
          Name:
            NameFull: Clark J
      – PersonEntity:
          Name:
            NameFull: Desai D
      – PersonEntity:
          Name:
            NameFull: Luo D
      – PersonEntity:
          Name:
            NameFull: Henry E
      – PersonEntity:
          Name:
            NameFull: Holz FG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2026 Apr
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1549-4713
          Numbering:
            – Type: volume
              Value: 133
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Ophthalmology
              Type: main
ResultId 1